Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY)
Key facts
- Who runs it
- Annetine Gelijns
- Where
- Ann Arbor, Atlanta, Baltimore, Bay Shore, Boston, Charleston, Charlottesville, Cleveland, Dallas, Durham, Kansas City, Lebanon, Los Angeles, Manhasset, Morgantown, New Orleans, New York, Philadelphia, Portland, San Francisco, Stanford, and Staten Island, United StatesSee the 28 sitesAlso in 4 other countries, 37 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 450 people enrolled
- Started
- 21 Feb 2022
- Expected to end
- 31 Jan 2034
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Mitral valve repair
- Transcatheter edge-to-edge repair
- Record updated
- 27 October 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- Adult patients ≥60 years with moderately-severe or severe (3+ or 4+/4+) primary degenerative (Carpentier type II) MR defined by transthoracic echocardiography
- Clinical indication for MV intervention and anatomic candidate for both surgical MV repair and transcatheter edge-to-edge repair (TEER) per local heart team assessment with central eligibility committee verification
- Patients across the surgical risk spectrum (low, intermediate, and high risk) depending on local heart team assessment and central eligibility committee verification (see ACC/AHA 2020 guidelines for the management of patients with valvular heart disease)
- Patients with AF who meet an indication for a concomitant ablation procedure be included provided the local heart team and central eligibility committee decide they are eligible for both catheter-based and surgical ablation
- Ability to perform 6-minute walk test (6MWT) and complete Kansas City Cardiomyopathy Questionnaire (KCCQ) instrument
Who cannot take part
- Febrile illness within 30-days prior to randomization
- Any prior mitral valve intervention or any prior repair of atrial septal defect
- Any prior MV intervention or any prior repair of atrial septal defect
- Need for any of the following concomitant procedures: aortic valve or aortic surgery, tricuspid valve surgery
- Need for any emergency intervention or surgery
- Treatment with another investigational drug or other intervention, assessment of which has not completed the primary endpoint or that clinically interferes with the present study endpoints
- Presence of an IVC filter or permanent pacing/ICD leads that would interfere with TEER per local heart team assessment
- Known allergic reactions to intravenous contrast
- Any contraindication to systemic heparinization including active bleeding diatheses, and heparin induced thrombocytopenia
- Hemodynamic instability defined as cardiac index <2.0 l/min/m2 or systolic blood pressure <90mmHg or need for inotropic support or any mechanical circulatory support
- Co-morbid medical or oncologic condition for which local heart team believes that survival beyond 2 years is unlikely
- Left ventricular ejection fraction <25%
- Non-degenerative types of primary MR (e.g., cleft leaflet)
- Secondary or functional MR
- Hypertrophic obstructive cardiomyopathy
- Any absolute contraindication to transesophageal echocardiography
- Patients with CAD requiring revascularization
- Active endocarditis
- Intracardiac mass or thrombus
- Active substance abuse
- Suspected inability to adhere to follow-up
Other criteria
- The patient population for this trial consists of adults with severe, primary degenerative MR for whom the local heart team has verified that an indication for MV intervention is present and for whom both transcatheter edge-to-edge and surgical repair strategies are anatomically feasible. Specific inclusion and exclusion criteria are listed below. All patients who meet eligibility criteria will be included in the study regardless of gender, race, or ethnicity
Where in United States
Also in 4 other countries, 37 sites
- University of Michigan HospitalAnn Arbor, United States
- Emory UniversityAtlanta, United States
- Emory University Hospital MidtownAtlanta, United States
- Piedmont Heart InstituteAtlanta, United States
- The Johns Hopkins HospitalBaltimore, United States
- Northwell - South ShoreBay Shore, United States
- Brigham and Women'sBoston, United States
- Massachusetts General HospitalBoston, United States
- Medical University of South CarolinaCharleston, United States
- University of Virginia Medical CenterCharlottesville, United States
- Cleveland ClinicCleveland, United States
- Baylor Scott and WhiteDallas, United States
- Duke University HospitalDurham, United States
- Saint Luke's Hospital of Kansas City/MidAmerica Heart and Lung SurgeonsKansas City, United States
- Dartmouth Hitchcock Medical CenterLebanon, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Keck Hospital of the University of Southern CaliforniaLos Angeles, United States
- Northwell Health - North ShoreManhasset, United States
- West Virginia University HospitalMorgantown, United States
- Ochsner ClinicNew Orleans, United States
- New York Presbyterian/Columbia University Medical CenterNew York, United States
- Northwell Health - Lenox HillNew York, United States
- Weill Cornell Medicine-New York Presbyterian HospitalNew York, United States
- Hospital of the University of PennsylvaniaPhiladelphia, United States
- Maine Medical CenterPortland, United States
- University of California San FranciscoSan Francisco, United States
- Stanford UniversityStanford, United States
- Northwell Staten Island University HospitalStaten Island, United States
About the trial
What the trial wants to find out
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany, Spain, and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.
The 2 groups in the trial
- Surgical mitral valve repairExisting treatment, for comparison
Patients who are randomized to the surgical arm will undergo mitral surgery.
Treatment: Mitral valve repair
- Transcatheter edge-to-edge repairExisting treatment, for comparison
In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 October 2026